title: How innovative are pharmaceutical innovations?: the case of medicines financed through add-on payments outside of the French DRG-based hospital payment system.
abstract: OBJECTIVE
  To analyze the characteristics of inpatient medicines placed on the list of innovative high-cost medicines funded in addition to DRG-based payment, and to identify whether they really are innovative and/or high-cost.
  
  
  METHODS
  The medicines placed on the list of innovative and high-cost medicines were analyzed on the basis of criteria describing their innovative nature and cost. They were categorized as innovative and high-cost, only high-cost, only innovative and neither innovative nor high-cost.
  
  
  RESULTS
  Among the medicines financed in addition to DRG-based payment, 25.5% were classified as innovative and high-cost, 23.5% only high-cost, 22.9% only innovative and 28.1% neither innovative nor high-cost.
  
  
  CONCLUSIONS
  The list of innovative and high-cost medicines contains medicines other than innovative and high-cost medicines. Stricter criteria for placing medicines on this list should be considered in order to limit the increase in expenditure.
authors.affiliation: Droit et économie pharmaceutiques (DEPH), Université Bordeaux Segalen, France. inna.gridchyna@etud.u-bordeaux2.fr
authors.forename: Inna
authors.initials: I
authors.lastname: Gridchyna
authors.forename: Marine
authors.initials: M
authors.lastname: Aulois-Griot
authors.forename: Catherine
authors.initials: C
authors.lastname: Maurain
authors.forename: Bernard
authors.initials: B
authors.lastname: Bégaud
mesh_terms: D003953:Diagnosis-Related Groups / Q000191:economics*; D004059:Diffusion of Innovation; D011307:Drug Prescriptions / Q000191:economics*; D017850:Economics, Pharmaceutical; D005602:France; D006291:Health Policy; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D011445:Prospective Payment System; D012051:Reimbursement Mechanisms